Nautilus Biotechnology
Biotech tools / proteomicsUSA
📉 Public < $1B
Peak $1.5 BillionToday
−85%
from peak
- 🦄Became a unicorn2021
- 📈Peak valuation$1.5 Billion ’21
- 💔Became a Unitard2022
- 💸Last valuation~$229M
Current status
Public (Nasdaq: NAUT); market cap ~$0.1B; product launch delayed to 2026, 16% layoffs (2025).
Live · NAUT· NasdaqCM
as of 2026-06-29
$1.80▼ 21.86% today
≈ $229 Million market cap · −84.7% from peak
How it happened
Nautilus Biotechnology aimed to map the entire human proteome with a single-molecule protein-analysis platform, and went public in June 2021 via a SPAC merger with Perceptive Advisors' Arya Sciences Acquisition Corp III, trading above $10 a share for a valuation over $1B. The product proved hard to commercialize: launch timelines slipped repeatedly (now targeted for late 2026), losses mounted and the stock fell more than 90%. By 2025 Nautilus had cut 16% of staff and was worth only around $100M — a fraction of its debut.
Source: Businesswire / GeekWire / SEC (SPAC merger with Arya Sciences Acquisition Corp III, closed June 2021, traded >$10/share at >$1B; ~$105M market cap 2025; commercial platform delayed to 2026; 16% layoffs)
